Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Emerging drugs for the treatment of angina pectoris|
|Citation:||Expert Opinion on Emerging Drugs, 2016; 21(4):365-376|
|Publisher:||Taylor & Francis|
|Cher-Rin Chong, Gao J Ong and John D Horowitz|
|Abstract:||Introduction: Angina pectoris, or symptomatic myocardial ischaemia, reflects an impairment of coronary blood flow, and usually a deficiency of available myocardial energetics. Treatment options vary with the precise cause, which may vary with regards to the roles of increased myocardial oxygen demand versus reduced supply. Traditionally, organic nitrates, β-adrenoceptor antagonists, and non-dihydropyridine calcium antagonists were the only commonly used prophylactic anti-anginal agents. However, many patients failed to respond adequately to such therapy, and/or were unsuitable for their use. Areas covered: A number of ‘new’ agents have been shown to represent ancillary forms of prophylactic anti-anginal therapy and are particularly useful in patients who are relatively unsuitable for either percutaneous or surgical revascularisation. These include modulators of myocardial metabolic efficiency, such as perhexiline, trimetazidine and ranolazine, as well as high dose allopurinol, nicorandil and ivabradine. The advantages and disadvantages of these various agents are summarized. Expert opinion: ‘Optimal’ medical treatment of angina pectoris now includes use of agents primarily intended to reduce risk of infarction (e.g. statins, aspirin, ACE inhibitors). In patients whose angina persists despite the use of ‘standard’ anti-anginal therapy, and who are not ideal for invasive revascularization options, a number of emerging drugs offer prospects of symptomatic relief.|
|Keywords:||Anti-anginal; myocardial energetics; carnitine palmitoyltransferase-1; perhexiline|
|Rights:||© 2016 Informa UK Limited, trading as Taylor & Francis Group|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.